The New Reality for Indian Pharma: Navigating Trump’s 200 Percent Tariff Plan
The pharmaceutical landscape just changed. US President Donald Trump announced a aggressive new tariff schedule targeting imported generic medicines. For India—the self-proclaimed "pharmacy of the world"—this is not just a policy shift. It is a fundamental challenge to a business model that has defined the global drug supply chain for decades. The Timeline of the Shift The proposal is structured in three distinct stages. It gives manufacturers a finite window to adjust their operations before the financial pressure hits full force. August 1, 2026 – July 31, 2028 : Zero percent tariff. Generic drugs continue to enter the US market duty-free during this two-year transition period. August 1, 2028 : A 100 percent tariff takes effect for all imported generic medicines. August 1, 2029: The levy doubles to 200 percent, creating a near-prohibitive environment for foreign-made generics. Trump announced the plan via social media, framing it as a direct "penalty" for compan...